Category: ABPI

  • Post-Brexit medicines regulation must have international scope

    Post-pandemic, post-Brexit Britain must create a regulatory framework that both defines and aligns with international standards, or risk being left behind. If the UK creates regulatory frameworks that drastically diverge from those of its “science allies”, it could become a late – or even no – launch market for new treatments. The need for companies […]

  • Getting better at measuring international uptake of medicines?

    In part one of a two-piece series, Leela Barham looks at whether we are getting better at measuring international uptake of medicines. The publication of a new report from healthcare analytics firm LOGEX, with the Institute for Rational Use of Medicine (IVM), on uptake in England should provide plenty of food for thought for the […]

  • Industry welcomes boost to health research in UK budget

    Groups representing the biopharma industry have welcomed an increase in health-specific R&D to £5 billion in the UK autumn budget, despite a longer timeline for reaching the target of £22 billion in overall R&D spending. The Association of the British Pharmaceutical Industry (ABPI) and BioIndustry Association (BIA) both said that the increase acknowledges the enormous […]

  • UK’s clinical research recovering slower than Euro peers, says ABPI

    The pandemic had a negative effect on clinical research across all countries, but the UK seems to be taking longer than others to recover, according to a report from the Association of the British Pharmaceutical Industry (ABPI). The industry body maintains however that the UK can bounce back strongly if it adopts the innovative approaches […]

  • Blueprints for UK pharma-NHS joint working

    Joint working could hold at least part of the answer to getting the NHS back on its feet after COVID, according to the ABPI. As the NHS begins to recover from the biggest crisis in its history, the biopharmaceutical industry is stepping up to the plate to offer its support and a new online repository of […]

  • Collaborate to simplify cancer trials and accelerate post-pandemic recovery

    How could simplifying the administration of clinical trials help cancer diagnosis, care, and treatment levels to exceed pre-pandemic levels? Amanda Barrell reports from the ABPI Scotland cancer roundtable discussion. Work to get Scotland’s cancer services back to full strength following the pandemic has already begun, and the pharmaceutical industry has pledged to play its part. […]

  • How to balance the patient voice atop the shifting plates of HTA

    The tectonic plates of healthcare technology assessment (HTA) have shifted – but where does the patient voice fit within this new evaluation paradigm? Recent advances in medical science, from genomics and gene therapies to artificial intelligence (AI), have transformed the healthcare landscape, and triggered a review of NICE’s methods and processes. Consultation on the proposals […]

  • Dementia, cancer headline UK’s 10-year plan for life sciences sector

    The UK’s long-awaited Life Sciences Vision strategy has been published, setting out the government’s stall as it tries to deliver on its promise to keep the country at the forefront of the sector. The document published today lays out seven healthcare “missions” for the UK’s industry as it tries to double down on the success […]

  • A life sciences vision to deliver health, wealth and resilience for the UK

    The ABPI’s chief executive Dr Richard Torbett outlines a new ‘vision’ and 10-year strategy for UK life sciences, launched by the government today. After an extraordinary year of science versus disease, the UK has cemented itself at the forefront of the global response to COVID-19. What has been achieved in just 18 months is nothing […]

  • ABPI launches 2021 Code of Practice

    The Association of the British Pharmaceutical Industry (ABPI) has launched its 2021 Code of Practice to help companies operate to high ethical standards.   The ABPI Code of Practice is the industry’s commitment to operate in a professional, ethical, and transparent manner, for the benefit of patients and the public. It is independently administered by the […]

  • UK highlights life sciences’ key role in post-COVID recovery

    The UK government used the Queen’s Speech to set out its ambition to make the country a leader in life sciences, garnering a warm response from industry groups.  The speech – an opportunity for Boris Johnson’s government to set out its plans for the year ahead after consolidating its position in last week’s local elections […]

  • Creating a global life sciences superpower from the lessons of COVID

    It’s time to take what the UK has learnt about the “Holy Trinity” of government, academia, and industry and apply it to creating a “life sciences superpower”, says health secretary Matt Hancock. The UK’s life sciences industry has “achieved in months what usually takes years” – and in doing so has built a solid foundation […]

  • Cancer services should be rebuilt after COVID disruption, experts say

    There is a pressing need for a joined-up cancer strategy to reverse the impact of the COVID-19 pandemic, according to a new report from the UK’s pharma industry. The Association of the British Pharmaceutical Industry (ABPI) report said that the UK must be more ambitious with its cancer strategy if it is to compete with […]

  • Stay calm and carry on: How to implement the updated ABPI code

    Don’t panic – that’s the message from one ABPI code expert who tells Amanda Barrell it’s time to take stock and prioritise. Compliance managers have less than six months to rewrite processes and procedures in line with the updated ABPI code of practice before it becomes enforceable in July. But it doesn’t all have to […]

  • VPAS: Achievement so far on objectives for the economy and innovation

    In the third part of this series taking stock of the 2019 Voluntary Scheme for Branded Medicines Pricing and Access objectives, Leela Barham looks at the third VPAS objective that relates to the economy and innovation. The objectives for the economy and innovation are to: deliver a net benefit to the UK economy overall; and support the […]

  • VPAS: Achievements so far on affordability

    In the second part of this series taking stock of the 2019 Voluntary Scheme for Branded Medicines Pricing and Access objectives, Leela Barham looks at the second VPAS objective that relates to affordability (spoiler alert: government gets millions in payments). The affordability objective is broken down further to: ensure that the Voluntary Scheme contributes to […]

  • UK parliament backs EU trade deal, as industry sifts through detail

    The post-Brexit trade deal agreed on Christmas Eve has been overwhelmingly backed by the UK parliament, providing some degree of stability – but also plenty of disruption – for the coming months and years. The UK is leaving the EU’s single market and customs union, but the deal means tariffs on goods won’t be imposed […]

  • 2020 in review: COVID-19 and patient centric clinical trials

    The trials and tribulations of 2020 have brought the vital role of research, pharma, and biotech into sharp focus. But how has the push to develop treatments and vaccines for SARS-CoV-2 affected the industry’s commitment to patient centricity? This time last year, researchers and industry players were working hard to embed patient centricity and engagement […]

  • Health inequalities: A societal challenge that needs a cross-sector solution

    COVID-19 has laid the UK’s health inequalities bare and created an imperative for the NHS to develop a step-change in how it cares for diverse and marginalised communities. Health inequality is the “greatest societal challenge of our time”, according to a briefing document calling for a system-wide solution. The report was published by the Association […]

  • Brexit could hinder access to coronavirus vaccines, says pharma group

    The UK’s pharma industry trade body has warned that Brexit could derail the government’s efforts to get coronavirus vaccines to the population, but welcomed other measures in this week’s spending review aimed at reviving the economy after the pandemic. In the build-up to chancellor Rishi Sunak’s announcement in the House of Commons, the Association of […]

  • Government needs strategy to kick-start R&D after COVID, says pharma body

    The UK has been leading research into the COVID-19 outbreak, according to the country’s pharma trade body, but there needs to be a strategy to restart trials into other diseases. The Association of the British Pharmaceutical Industry (ABPI) said that restarting research into diseases such as cancer would be the first step in the journey […]

  • Behind the scenes of the new ABPI Code of Practice

    For over 60 years the ABPI Code of Practice has been key to the UK industry’s self-regulation, and now, as pharma is experiencing its most intense period of change in decades, a new update seeks to bring the Code in line with the modern sector. With the new Code now in its consultation stage, we […]

  • Tackling multimorbidity through collaboration

    As populations age, multimorbidity becomes an increasingly pertinent issue for healthcare systems. A new action group from the ABPI seeks to bring the NHS, academia and industry together to find new ways to address the problem. The Association’s Dr Sheuli Porkess and Professor Janet Lord from the University of Birmingham tell us more. Multimorbidity is […]

  • Fearing Brexit chaos, UK asks pharma to build six-week drug stockpile

    The UK government has asked pharma companies to build a six-week stockpile of drugs and find alternative shipping routes to the congested Dover-Calais crossing as the country heads for Brexit at the end of the year. In a letter, Steve Oldfield, chief commercial officer at the Department of Health and Social Care, said the government […]